The effect of β-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure

Journal of Heart and Lung Transplantation

Volumn 22, Issue 1, 2003, Pages 70-77

  Peterson, Linda R ^a   Schechtman, Kenneth B ^a   Ewald, Gregory A ^a   Geltman, Edward M ^a   Meyer, Timothy ^a   Krekeler, Pamela ^a   Rogers, Joseph G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL;

ADULT; AIR CONDITIONING; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DRUG EFFECT; EXERCISE; FEMALE; HEART FAILURE; HEART GRAFT; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOTOPIC TRANSPLANTATION; OXYGEN CONSUMPTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PROGNOSIS;

EID: 0037227623     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00473-4     Document Type: Article

References (28)

1. 2 a simple yet enduring standard . Circulation. 101:2000;1080-1082.
2. Szlachcic J., Massie B., Kramer B., Topic N., Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol. 55:1985;1037-1042.
3. Likoff M.J., Chandler S.L., Kay H.R. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic or dilated cardiomyopathy. Am J Cardiol. 59:1987;634-638.
4. Mancini D.M., Eisen H., Kussmaul W., Mull R., Edmunds L.H., Wilson J.R. Value of peak exercise consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 83:1991;778-786.
5. Stelken A.M., Younis L.T., Jennison S.H., et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 27:1996;345-352.
6. Cahalin L.P., Mathier M.A., Semigran M.J., Dec G.W., DiSalvo T.G. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 110:1996;325-332.
7. Cohn J., Johnson G., Shabetai R., et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 87:1993;VI-5-16.
8. Aaronson K.D., Mancini D.M. Is percentage of predicted maximal exercise oxygen consumption a better predictor of survival than peak exercise oxygen consumption for patients with severe heart failure? J Heart Lung Transplant. 14:1995;981-989.
9. Pardaens K., Cleemput J.V., Vanhaecke J., Fagard R.H. Peak oxygen uptake better predicts outcome than submaximal respiratory data in heart transplant candidates. Circulation. 101:2000;1152-1157.
10. Van den Broek S.A.J., van Veldhuisen D.J., de Graeff P.A., Landsman M.L.J., Hillege H., Lie K.I. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 70:1992;359-363.
11. Chomsky D.B., Lang C.C., Rayos G.H., et al. Hemodynamic exercise testing. Circulation. 94:1996;3176-3183.
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomized trial . Lancet. 353:1999;9-13.
13. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
14. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
15. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
16. Metra M., Giubbini R., Nodari S., et al. Differential effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol vs. carvedilol. Circulation. 102:2000;546-551.
17. 2 max to training in 60-71 yr-olds. J Appl Physiol. 71:1991;2004-2011.
18. Di Lenarda A., Maria R.D., Gavassa A., et al. Long term survival effect of metoprolol in dilated cardiomyopathy. Heart. 79:1998;337-344.
19. Waagstein F., Bristow M.R., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
20. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction the CAPRICORN randomized trial . Lancet. 357:2001;1385-1390.
21. Metra M., Nodari S., D'Aloia A., et al. A rationale for the use of [beta]-blockers as standard treatment for heart failure. Am Heart J. 139:2000;511-521.
22. Colucci W.S., Packer M., Bristow M.R., et al. Congestive heart failure/myocardial disease carvedilol inhibits clinical progression in patients with mild symptoms of heart failure . Circulation. 94:1996;2800-2806.
23. Hobbs R.E. Should patients with severe heart failure be treated with beta-blockers? Cleveland Clin J Med. 68:2001;469-470.
24. Myers J., Gullestad L., Vagelos R., et al. Cardiopulmonary exercise testing and prognosis in severe heart failure 14 mL/kg/min revisited . Am Heart J. 139:2000;78-84.
25. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Congestive heart failure/myocardial disease carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure . Circulation. 94:1996;2807-2816.
26. Myers J., Gullestad L., Vagelos R., et al. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med. 129:1998;286-293.
27. Moss A.J., Zoreba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346:2002;877-883.
28. Dorian P., Cass D., Schwartz B., et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 346:2002;884-890.